On January 22, 2018, we expect to file with the Securities and Exchange Commission a Prospectus Supplement in which we will disclose that we had approximately $176.4 million in cash, cash equivalents and investments at December 31, 2017. On January 22, 2018, we provided an update to our risk factors, as last disclosed in our Quarterly Report on For
LONDON, Jan. 22, 2018 Industry disruptor Robert Wessman, the CEO of rapidly growing generic pharmaceuticals company Alvogen, shares his thoughts on the latest market trends in the new edition of World Finance magazine. Among this innovative group of' next generation' pharmaceutical companies is Reykjavik- based Alvogen. Though it was only establi
Biopharmaceutical company Biocon and Sandoz, a unit of Swiss pharma giant Novartis, will partner to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients, the two companies said. We are pleased to announce our collaboration with Sandoz for developing a set of next generation biosimilar products.
Amgen Inc. and Allergan plc said the European Commission approved Mvasi, a biosimilar of Avastin bevacizumab. In September, FDA approved the drug as Mvasi bevacizumab-awwb for all cancer types on Avastin's U.S. label except ovarian cancer. Roche and its Genentech Inc. unit market Avastin.
Findings on Psoriasis Detailed by K. Papp and Co-Authors. By a News Reporter-Staff News Editor at Clinical Trials Week Data detailed on Skin Diseases and Conditions- Psoriasis have been presented. According to news reporting originating from Waterloo, Canada, by NewsRx correspondents, research stated, "ABP 501, a U.S.A. Food and Drug Administrati
The global market for inhalation and nasal spray generic drugs features a largely fragmented, not to mention intensely competitive owing to pricing pressures, vendor landscape, with the top four companies accounting for a nearly 46% of the overall ma...
Effective January 17, 2018, Timothy C. Crew, Lannett Company, Inc.' s chief executive officer, has been appointed to the Company's Board of Directors in order to fill a newly created vacancy as a result of the Board of Directors increasing the size of the board from six to seven members. He has more than 25 years of experience in the generic and br
Are you sick and tired of unpronounceable drug names? If you think it's bad now, just wait. When modern pharmaceuticals become available generically in the next several years, it will become next to impossible.
According to news reporting originating in Gifu, Japan, by NewsRx journalists, research stated, "Factors influencing generic drug use must be considered when new drug policies are established and initiatives are implemented to promote generic drug use. The news reporters obtained a quote from the research from Gifu Pharmaceutical University, "We co
A major deal between Novartis subsidiary Sandoz and Bangalore, India- based biosimilar player Biocon confirms the rise of these close copies of biodrug major brands, according to New York City- based healthcare market research firm Kalorama Information. Kalorama estimates that the global market for biosimilar products has grown to be worth almost
THOUSAND OAKS- The process of drug development is costly and time consuming. According to the America Invents Act, signed into law by President Barack Obama on September 16, 2011, the first to file the patent application, regardless of the date of invention, is granted the patent. In the U.S., manufacturers of pharmaceutical drugs have the rights t
Biocon stock surged 6% after the company entered into a global partnership with Sandoz to develop, manufacture and commercialize multiple biosimilar in immunology and oncology. Sandoz will lead commercialization in North America and the EU while Biocon will lead commercialization in Rest of the World. Biocon is a fully-integrated biopharma player w
Jan. 21 It's now hard to find a corner of the health care system where SSM Health does not operate. This week Creve Coeur- based SSM Health said it was launching a nonprofit generic drug company in partnership with other major nonprofit health systems. "It's very purposeful," Laura Kaiser, president and CEO of SSM Health, said of the health syst
Cadila Healthcare reported that its Dabhasa plant has cleared a USFDA audit with zero observations. Cadila Healthcare is currently trading at Rs447.15, up by Rs11.05 or 2.53% from its previous closing of Rs436.1 on the BSE. Cadila Healthcare is a fully-integrated, pharmaceutical company with strong presence in the formulations and CRAMS businesses.
Amgen and Allergan plc have that the European Commission has granted marketing authorisation for MVASI. The European Commissions approval of MVASI marks a significant milestone for both Amgen and the oncology community, providing a biosimilar for a medicine which is used across multiple types of cancer, said Sean E Harper, MD, executive vice presid
The Japanese government is planning new measures to help Japanese companies construct pharmaceutical factories in Asian countries, where labour costs are lower than in Japan, to encourage the production of more generic drugs. The Headquarters for Healthcare and Medical Strategy Promotion chaired by Prime Minister Shinzo Abe is proceeding with the s
Many of the major not-for-profit hospital groups have tried their hand an manufacturing and making generics to combat the shortages of medicines as well as the high costs of branded medications. This move bypasses the monopoly held by the pharmaceutical companies. Hospital groups that are joining hands in this venture include Intermountain Health,.
The deal with Novartis` subsidiary Sandoz comes after Biocon resolved problems at its manufacturing facility that forced it to withdraw EU filings for biosimilar versions of Roche`s breast cancer drug Herceptin and Amgen`s long-acting white cell booster Neulasta last August at the request of the EMA. The companies will share responsibility for...
The agreement announced this week will see Novartis subsidiary Sandoz share the development and production of an undisclosed number of third wave biosimilar candidates with Indian biomanufacturer Biocon. The biosimilar assets that are part of this agreement complement our existing portfolio in immunology and oncology, Sandoz spokesperson Chris...
Celltrion, a Korean biopharmaceutical firm, said Friday that its net profits soared 82.1 percent in 2017 from a year earlier on robust sales of its biosimilar drug Remsima overseas. Celltrion said its operating profit more than doubled to 517 billion won in 2017 from 253 billion won a year earlier. Celltrion also began selling another biosimilar dr
-SOHM, Inc. a globally-known generic pharmaceutical manufacturer, announces today that it has signed a binding Letter of Intent with a Canadian Institutional Investor for a sizable investment in SOHM. Management is confident that by incorporating blockchain technologies with its core business, SOHM will create a competitive advantage in the field o
THOUSAND OAKS- Amgen and Allergan plc. announced Thursday that the European Commission has granted marketing authorization for MVASI. Amgen and Allergan said they are committed to developing high-quality biosimilars with a robust analytic and clinical package. Amgen noted that MVASI is the first targeted cancer biosimilar from the company's portfol
Utah- based Intermountain Healthcare is leading the collaboration that includes two St. Louis area health systems, Ascension and SSM Health, in addition to Michigan- based Trinity Health and the Department of Veterans Affairs. The generic drug company will either become an FDA- approved manufacturer or subcontract the work. One example of a pricey
The government is planning new measures to help Japanese companies construct pharmaceutical factories in Asian countries, where labor costs are lower than in Japan, to encourage the production of more generic drugs, The Yomiuri Shimbun has learned. The Headquarters for Healthcare and Medical Strategy Promotion chaired by Prime Minister Shinzo Abe i